Hohimer Wealth Management LLC Buys Shares of 16,543 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Hohimer Wealth Management LLC bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 16,543 shares of the biopharmaceutical company’s stock, valued at approximately $329,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CPRX. Susquehanna Fundamental Investments LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $258,000. Integral Health Asset Management LLC acquired a new stake in Catalyst Pharmaceuticals in the second quarter valued at approximately $4,260,000. GSA Capital Partners LLP bought a new stake in Catalyst Pharmaceuticals in the third quarter worth approximately $625,000. Capstone Investment Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth $708,000. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Catalyst Pharmaceuticals by 146.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock worth $7,285,000 after purchasing an additional 217,956 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

CPRX has been the subject of several analyst reports. Truist Financial lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, Stephens initiated coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $22.11 on Wednesday. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of 18.74, a P/E/G ratio of 3.36 and a beta of 0.75. The firm has a fifty day moving average price of $21.52 and a two-hundred day moving average price of $19.07. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $13.00 and a fifty-two week high of $24.27.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.